SYSTEMATIC REVIEW article

Front. Pharmacol.

Sec. Renal Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1559314

This article is part of the Research TopicReviews in Renal Pharmacology: 2024View all 11 articles

Tetramethylpyrazine and Renal Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis of Preclinical Studies TMP and Renal I/R injury

Provisionally accepted
Zhongmei  FUZhongmei FU1Lianyan  JiangLianyan Jiang1Xiaojuan  SuXiaojuan Su2Hua  WangHua Wang3Mingquan  LiMingquan Li4*
  • 1Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 2Hubei provincial hospital of Traditional Chinese Medicine, Hubei, wuhan, China
  • 3Maternal and Child Health Care Hospital, Kunming, Kunming Maternal and Child Health Care Hospital, China
  • 4chendu, Hospital of Chengdu University of Traditional Chinese Medicine, China

The final, formatted version of the article will be published soon.

The aim of this systematic review and meta-analysis is to synthesize the effects and mechanisms of Tetramethylpyrazine (TMP) on renal outcomes in animal models of renal I/R injury.Methods: Animal studies from seven electronic databases were searched up to October 2024. The risk of bias of the selected studies was assessed using the SYRCLE risk of bias tool. Standardized mean difference (SMD) or mean difference (MD) were estimated for the effects of TMP on serum creatinine (Scr), blood urea nitrogen (BUN), oxidative stress, inflammation and apoptotic. Randomeffects models were used to summarize results. Heterogeneity was expressed as I2. Subgroup analyses were used to clarify the sources of heterogeneity. Egger's test was used to assess publication bias. Sensitivity analyses were used to assess the robustness of the results. Statistical analysis was performed using RevMan 5.3 software.Results: Thirty studies involving 559 animals were identified for analysis. TMP treatment significantly decreased Scr (SMD = 2.35, 95 % CI: -2.97 to -1.72, P < 0.05), BUN (SMD = -2.4, 95 % CI: -3.01 to -1.79, P < 0.05). TMP treatment significantly improved oxidative stress expression (i.e. SOD, MDA, GSHPX, CAT, TAC) and alleviated inflammation levels (i.e. TNF-α, ICAM-1, IL-6, IL-10, NLRP3). TMP treatment also regulate the expression of apoptosis-related proteins (i.e. bcl-2, Bax, caspase 3, Caspase-12 and GRP78).Conclusions: TMP could improve renal outcomes and alleviate injury through multiple signaling pathways. However, positive results should be treated with caution due to the significant heterogeneity and poor quality of the included studies.Two authors independently conducted a comprehensive search for animal studies investigating TMP in the context of renal ischemia-reperfusion injury, covering the period from the inception of the respective databases to October 2024.

Keywords: Tetramethylpyrazine, renal ischemia-reperfusion injury, Preclinical study, Meta-analysis, Systematic review

Received: 12 Jan 2025; Accepted: 14 May 2025.

Copyright: © 2025 FU, Jiang, Su, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mingquan Li, chendu, Hospital of Chengdu University of Traditional Chinese Medicine, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.